ICON8 trial reaffirms standard dosing in ovarian cancer chemo #ESMO17

da Salute H24 — 4 settembre 2017 alle 18:43


European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 Congress in Madrid. Continua »

AntonioCaperna

Scrivi un commento